Your browser doesn't support javascript.
loading
Phase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2.
Ammoun, Sylwia; Evans, D Gareth; Hilton, David A; Streeter, Adam; Hayward, Christopher; Hanemann, C Oliver.
Afiliação
  • Ammoun S; Institute of Translational and Stratified Medicine, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK.
  • Evans DG; Regional Genetic Service, St Mary's Hospital, Manchester, UK.
  • Hilton DA; University Hospitals Plymouth NHS Trust, Plymouth, UK.
  • Streeter A; Medical Statistics, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK.
  • Hayward C; Peninsula Clinical Trials Unit, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK.
  • Hanemann CO; Institute of Translational and Stratified Medicine, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK Oliver.Hanemann@plymouth.ac.uk.
J Neurol Neurosurg Psychiatry ; 90(10): 1184-1187, 2019 10.
Article em En | MEDLINE | ID: mdl-30718294

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neurofibromatose 2 / Sorafenibe / Antineoplásicos Limite: Adult / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neurofibromatose 2 / Sorafenibe / Antineoplásicos Limite: Adult / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article